A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination With Standard Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Dociparstat sodium (Primary) ; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms DASH AML
- Sponsors Chimerix
Most Recent Events
- 18 Mar 2024 Status changed from active, no longer recruiting to discontinued.
- 15 Jun 2022 Planned End Date changed from 15 Feb 2026 to 31 Dec 2022.
- 15 Jun 2022 Planned primary completion date changed from 1 May 2024 to 31 Dec 2022.